Heterozygous PU.1 mutations are associated with acute myeloid leukemia

Blood

Volumn 100, Issue 3, 2002, Pages 998-1007

  Mueller, Beatrice U ^a,b,c,d,e   Pabst, Thomas ^a,b,c,d,e   Osato, Motomi ^a,b,c,d,e   Asou, Norio ^a,b,c,d,e   Johansen, Lisa M ^a,b,c,d,e   Minden, Mark D ^a,b,c,d,e   Behre, Gerhard ^a,b,c,d,e   Hiddemann, Wolfgang ^a,b,c,d,e   Ito, Yoshiaki ^a,b,c,d,e   Tenen, Daniel G ^a,b,c,d,e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION;

EID: 0036682473     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.3.998     Document Type: Article

References (51)

1. Chromosomal translocations in human cancer
2. The transcriptional control of hematopoiesis
3. Transcription factors, normal myeloid development, and leukemia
4. Myeloid transcription factors and development
5. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias
6. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
7. 0 acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21
8. Dominant negative mutations of CEBPA, encoding CCAAT/Enhancer Binding Protein-α (C/EBPα), in acute myeloid leukemia
9. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML): Implications for mechanisms of pathogenesis
10. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias
11. The macrophage and B cell-specific transcription factor PU.1 is related to the Ets oncogene
12. Hematopoietic lineage-restricted and stage-restricted expression of the Ets oncogene family member PU.1
13. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B
14. Inhibition of hematopoiesis by competitive binding of the transcription factor PU.1
15. The ETS-domain: A new DNA-binding motif that recognizes a purine-rich core DNA sequence
16. Activation of transcription by PU.1 requires both acidic and glutamine domains
17. The transcription factor PU.1 is required for the development of multiple hematopoietic lineages
18. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
19. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter
20. The macrophage transcription factor PU.1 directs tissue specific expression of the macrophage colony stimulating factor receptor
21. PU.1 (Spi-1) and C/EBPα regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells
22. PU.1 (Spi-1) and C/EBPα regulate the expression of the granulocyte-macrophage colony-stimulating factor receptor α gene
23. Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPα
24. Myeloid development is selectively disrupted in PU.1 null mice
25. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent
26. PU.1 regulates both cytokine dependent proliferation and differentiation of granulocyte/macrophage progenitors
27. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation
28. Multiple functional domains of AMLI: PU.1 and C/EBPα cooperate with different regions of AML1
29. Regulatory interactions between transcription factors and their role in hematopoietic lineage determination
30. C/EBPα bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts
31. Dimeric RFX proteins contribute to the activity and lineage-specificity of the interleukin-5 receptor α promoter through activation and repression domains
32. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells
33. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein α (C/EBPα) is critical for granulopoiesis
34. Luciferase reporter gene vectors for analysis of promoters and enhancers
35. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor
36. c-myc is a critical target for C/EBPα in granulopoiesis
37. Production of high-titer helper-free retroviruses by transient transfection
38. Lymphoid- and myeloid-specific activity of the PU.1 promoter is determined by the combinatorial action of octamer and ets transcription factors
39. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1
40. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP
41. A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex
42. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: Functional antagonism in erythroid cells
43. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding
44. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1 dependent transcription
45. Identification of a region which directs monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1)
46. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3′ enhancer activity
47. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation
48. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors
49. PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1
50. Diversification of haematopoietic stem cells to specific lineages
51. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice